Showing papers by "Tangfeng Lv published in 2013"
TL;DR: Skin rash after EGFR-TKI treatment may be an efficient clinical marker for predicting the response of patients with non-small cell lung cancer to EG FR-TKIs.
Abstract: Background
The aim of this study was to assess the role of skin rash in predicting the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the prognosis of patients with non-small cell lung cancer (NSCLC).
127 citations
TL;DR: Plasma mtDNA was an independent indictor with moderate discriminative power to predict the risk of post-traumatic SIRS in patients with acute traumatic injury.
Abstract: Background and Purpose
Mitochondrial DNA (mtDNA), a newly identified damage-associated molecular pattern, has been observed in trauma patients, however, little is known concerning the relationship between plasma mtDNA levels and concrete post-traumatic complications, particularly systemic inflammatory response syndrome (SIRS). The aim of this study is to determine whether plasma mtDNA levels are associated with injury severity and cloud predict post-traumatic SIRS in patients with acute traumatic injury.
83 citations
TL;DR: Therapy consisting of chemotherapy plus multitargeted antiangiogenic TKI was found to have specific advantages over chemotherapy alone in terms of PFS and ORR, and the toxicity was comparable between the two therapies.
Abstract: Background
Most patients with advanced non-small-cell lung cancer (NSCLC) require systemic chemotherapy. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors (TKI; e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, axitinib) has recently been evaluated in patients with NSCLC. However, the advantage of this therapy over chemotherapy alone in patients with advanced NSCLC remains largely unknown.
32 citations
TL;DR: Although similar in overall survival, chemotherapy plus vandetanib showed particular advantages over chemotherapy alone in terms of progression-free survival and overall response rate, and might be a safe and valid therapeutic option for advanced NSCLC patients.
14 citations